Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

Morgan Stanley’s analysis from November 2024 projected significant revenue growth, with estimates rising from RMB 123,851 million in 2023 to RMB 202,461 million by 2026. However, earnings per share ...

According to InvestingPro analysis, the stock is currently trading slightly below its Fair Value, suggesting potential upside opportunity. This comprehensive analysis delves into the company’s current ...

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by Pfizer. Now, he thinks ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

The dry AMD treatment market is experiencing unprecedented growth, driven by increasing disease awareness, rising prevalence of age-related eye cond ...